BackgroundAnal squamous cell carcinoma (ASCC) is one of the most frequent non-AIDS-defining neoplasias in HIV patients, mainly in MSM, and it has been associated with chronic infection with high-risk human papilloma virus (HR-HPV). Our main objective was to determine HR-HPV clearance and acquisition rates and related factors and their relationship with the incidence of HSILs and ASCC in anal mucosa of HIV+ MSM.
Patients and methodsThe study included consecutive HIV-infected MSM between May 2010 and December 2018. Data were gathered at baseline and annually on their sexual behavior, CD4 and CD8 levels, plasma HIV viral load, and results of anal cytology, HPV PCR, and high-resolution anoscopy.
ResultsOut of the 405 patients studied, 34.9% of patients cleared oncogenic genotypes (IQR: 37-69) within 49 months, and 42.9% acquired new genotypes within 36 months (IQR:12-60). In multivariate analysis, clearance was only significantly influenced by the duration of antiretroviral therapy (ART) (OR: 1.016, 95% CI 1.003-1.030). The incidence of HSILs was 30.86/ 1,000 patient-years and that of ASCC was 81.22/100,000 patient-years; these incidences were not influenced by the acquisition (acquired: 14.9% vs. non-acquired: 10.4%; p = 0.238) or clearance (cleared 11.4% vs. non-cleared: 13.2%; p = 0.662) rates of these viruses.
ConclusionsThe duration of ART appears to positively affect oncogenic genotype clearance in the anal mucosa of HIV+ MSM, although this clearance does not affect the incidence of HSILs or ASCC. The reduction in HSIL+ rate observed in our patients may be attributable to the bundle of measures adopted at our center. Competing interests: The authors have declared that no competing interests exist. 30-50 yrs, n (%) 244 (60.2) >50 yrs n (%) 38 (9.4) Retired, n (%), 95% CI 6 (1.5) Educational level No studies 40 (9.9) Primary studies 129 (31.9) Secondary studies 230 (56.7) University studies 22 (5.4) (3-7.5) Origin Europe 387 (95.6) Central America 17 (4.2) qHPV vaccine (2012-2014), n (%), 95% CI 66 (16.3) Age at first sexual intercourse, median (IQR) 18 (16-20) Number of lifetime male sex partners, median (IQR) 50 (15-150) Number of male sex partners during previous 12 months, (IQR) 1(1-7) Habitual use of condoms, n (%), 95%CI 294 (72.6) (68.2-77.4) Total number of sexual partners during follow-up, median (P25-P75) 54.5(20-154) History of anal/genital warts, n (%), (95%CI) 128 (31.6), (27.1-36.1) Anal/genital warts at baseline, n (%), (95%CI) 93 Time since HIV diagnosis (months), median (IQR) 25 (8-84)CD4 at diagnosis of HIV (cel/uL), (± SD) 448± 298.17 HIV viral load at diagnosis of HIV (log), mean (IQR) 4.61 (4.07-5.12) CD4 nadir (cells/uL), (± SD) 367.93±233.85 CD4 nadir < 200 cells/uL, n(%), 95% CI 97 (23.9), (20-28.5) CD4 cell count at baseline (cells/uL), (± SD) 689.64± 475.03 CD8 cell count at baseline (cells/uL), (± SD) 981.5±531.5 CD4 /CD8 ratio, mean, (± SD) 0.77±0.70 HIV viral load at baseline (log), median, IQR 0 (0-1.72) Undetectable: < 50 HIV RNA copies/mL of plasma n (%) 348 (85.9) History of AIDS ...